SAB Biotherapeutics Inc (SABS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.720.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SABS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | 1.3 | 2.2 | 23.9 | 60.9 | 55.2 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 49.3 | 34.4 | 30.3 | 16.5 | 36.4 | 57.2 | 27.9 |
| Operating Income | (71.8) | (49.0) | (42.9) | (38.1) | (28.9) | (13.4) | 20.6 |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 0.2 | — | 0.3 | 0.3 | 0.3 | 0.5 |
| Other Non-Operating Income / Expenses | 59.0 | 62.2 | 8.8 | (4.1) | 10.2 | (3.8) | — |
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| EBT, Incl. Unusual Items | — | 13.3 | — | (42.2) | (18.7) | (17.1) | 20.1 |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (12.8) | 13.3 | (34.1) | (42.2) | (18.7) | (17.1) | 20.1 |
| Per Share | |||||||
| Basic EPS | (0.16) | 0.22 | (3.68) | (7.64) | (4.31) | (0.63) | 0.79 |
| Diluted EPS | (0.16) | (0.79) | (3.68) | (7.64) | (4.31) | (0.63) | 0.74 |
| Basic Weighted Avg Shares | 79.8 | 19.3 | 9.3 | 5.5 | 4.4 | 27.3 | 25.4 |
| Diluted Weighted Avg Shares | 79.8 | 61.3 | 9.3 | 5.5 | 4.4 | 27.3 | 27.0 |
| Supplemental | |||||||
| EBITDA | — | (46.0) | (38.2) | (34.4) | (25.7) | (11.9) | 20.9 |
| EBIT | (71.8) | (49.0) | (42.9) | (38.1) | (28.9) | (13.4) | 20.6 |
| Effective Tax Rate | — | — | — | 0.0% | -0.1% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.